Literature DB >> 16979452

Adults with invasive pneumococcal disease: missed opportunities for vaccination.

Moe H Kyaw1, Carolyn M Greene, William Schaffner, Susan M Ray, Miriam Shapiro, Nancy L Barrett, Ken Gershman, Allen S Craig, Angela Roberson, Elizabeth R Zell, Anne Schuchat, Nancy M Bennett, Cynthia G Whitney.   

Abstract

BACKGROUND: The pneumococcal polysaccharide vaccine (PPV) can prevent invasive pneumococcal disease (IPD) in the elderly and those with certain underlying illnesses. However, vaccine uptake remains suboptimal. Identification of missed opportunities for vaccination could guide new strategies for improving uptake. Missed opportunities for vaccination were defined as one or more visits to a hospital, emergency room (ER), or main provider in the 2 years before infection among unvaccinated, adult IPD case-patients with a vaccine indication.
METHODS: Adults aged 18 years or older with IPD were identified in six Active Bacterial Core surveillance/Emerging Infections Program Network sites during a 1-year period in 2001 to 2003. Using chart review, patient/proxy interview, a main provider questionnaire, and vaccine questionnaires from additional providers, data were collected on demographics, vaccine indications, vaccine status, and recent healthcare encounters.
RESULTS: A total of 1878 cases were enrolled, and 83% had a vaccine indication. Of the 1177 cases with a vaccine indication and sufficient information on recent healthcare encounters, 617 (52%) were unvaccinated. Of these, 566 (92%) had one or more opportunities for vaccination, 54% were hospitalized, 58% had ER visits, and 76% visited their main provider in the 2 years before illness. The number of visits to main providers (median = 6) was higher than hospitalizations (median = 1), and ER visits (median = 1).
CONCLUSIONS: One or more missed opportunities for vaccination were documented in nearly all unvaccinated IPD case-patients with a vaccine indication. Most visited their main provider multiple times. Implementation of systematic PPV programs in outpatient settings will likely increase pneumococcal vaccine uptake among high-risk adults.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16979452     DOI: 10.1016/j.amepre.2006.06.007

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  6 in total

1.  Factors associated with pneumococcal vaccination among an urban elderly population in China.

Authors:  Shijun Liu; Erping Xu; Yan Liu; Yuyang Xu; Jun Wang; Jian Du; Xiaoping Zhang; Xinren Che; Wenwen Gu
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Trends in Invasive Pneumococcal Disease in Cancer Patients After the Introduction of 7-valent Pneumococcal Conjugate Vaccine: A 20-year Longitudinal Study at a Major Urban Cancer Center.

Authors:  Yeon Joo Lee; Yao-Ting Huang; Seong Jin Kim; Marina Kerpelev; Victoria Gonzalez; Anna Kaltsas; Genovefa Papanicolaou
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079

3.  The epidemiology of invasive pneumococcal disease in older adults in the post-PCV era. Has there been a herd effect?

Authors:  M Corcoran; I Vickers; J Mereckiene; S Murchan; S Cotter; M Fitzgerald; M McElligott; M Cafferkey; D O'Flanagan; R Cunney; H Humphreys
Journal:  Epidemiol Infect       Date:  2017-08       Impact factor: 4.434

Review 4.  Missed opportunities for improving practice performance in adult immunizations: a meta-narrative review of the literature.

Authors:  Natalia Loskutova; Craig Smail; Brian Webster; Kemi Ajayi; Julie Wood; Jennifer Carroll
Journal:  BMC Fam Pract       Date:  2017-12-22       Impact factor: 2.497

Review 5.  Pneumococcal Vaccination in Immunocompromised Hosts: An Update.

Authors:  Claire Froneman; Peter Kelleher; Ricardo J José
Journal:  Vaccines (Basel)       Date:  2021-05-21

6.  Outpatient-based pneumococcal vaccine campaign and survey of perceptions about pneumococcal vaccination in patients and doctors.

Authors:  Joon Young Song; Hee Jin Cheong; Jung Yeon Heo; Ji Yun Noh; Yu Bin Seo; In Seon Kim; Won Suk Choi; Woo Joo Kim
Journal:  Yonsei Med J       Date:  2013-03-01       Impact factor: 2.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.